Valuation: ALLOVIRPAR

Market Cap 49.21M 43.85M 40.6M 36.74M 69.22M 4.64B 70.04M 487M 191M 2.44B 185M 181M 7.78B P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -69.08M -61.56M -56.99M -51.57M -97.17M -6.52B -98.32M -683M -268M -3.43B -259M -254M -10.92B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day-1.98%
Current month-79.82%
Current year-79.82%
3 years 1.96
Extreme 1.96
57.15
5 years 1.96
Extreme 1.96
576.38
10 years 1.96
Extreme 1.96
1,126.08

Financials

2023 2024
Net sales - -
Net income -190M -170M -157M -142M -268M -17.97B -271M -1.88B -739M -9.45B -714M -699M -30.1B -58.77M -52.37M -48.49M -43.88M -82.67M -5.55B -83.65M -581M -228M -2.92B -220M -216M -9.29B
Net Debt -157M -139M -129M -117M -220M -14.77B -223M -1.55B -607M -7.76B -587M -575M -24.74B -118M -105M -97.59M -88.32M -166M -11.16B -168M -1.17B -459M -5.87B -444M -434M -18.7B
Projected Income Statement - Annual - ALLOVIRPAR
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change
26-10-22 US$1.980 -1.98%
26-10-21 US$2.020 -2.42%
26-10-20 US$2.070 +8.38%
26-10-19 US$1.910 -4.50%
26-10-16 US$2.000 -8.68%
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock